- Home
- CIGL vs SKYE Comparison
CIGL vs SKYE Comparison
Compare CIGL & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIGL
- SKYE
- Stock Information
- Founded
- CIGL 1997
- SKYE 2012
- Country
- CIGL Singapore
- SKYE United States
- Employees
- CIGL N/A
- SKYE N/A
- Industry
- CIGL Diversified Commercial Services
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- CIGL Consumer Discretionary
- SKYE Health Care
- Exchange
- CIGL Nasdaq
- SKYE Nasdaq
- Market Cap
- CIGL 52.8M
- SKYE 44.9M
- IPO Year
- CIGL 2025
- SKYE N/A
- Fundamental
- Price
- CIGL $1.80
- SKYE $1.31
- Analyst Decision
- CIGL
- SKYE Strong Buy
- Analyst Count
- CIGL 0
- SKYE 5
- Target Price
- CIGL N/A
- SKYE $14.75
- AVG Volume (30 Days)
- CIGL 15.3K
- SKYE 303.2K
- Earning Date
- CIGL 09-29-2025
- SKYE 11-10-2025
- Dividend Yield
- CIGL N/A
- SKYE N/A
- EPS Growth
- CIGL N/A
- SKYE N/A
- EPS
- CIGL N/A
- SKYE N/A
- Revenue
- CIGL $11,072,733.00
- SKYE N/A
- Revenue This Year
- CIGL N/A
- SKYE N/A
- Revenue Next Year
- CIGL N/A
- SKYE N/A
- P/E Ratio
- CIGL N/A
- SKYE N/A
- Revenue Growth
- CIGL 6.32
- SKYE N/A
- 52 Week Low
- CIGL $1.40
- SKYE $1.14
- 52 Week High
- CIGL $31.06
- SKYE $5.75
- Technical
- Relative Strength Index (RSI)
- CIGL N/A
- SKYE 39.90
- Support Level
- CIGL N/A
- SKYE $1.17
- Resistance Level
- CIGL N/A
- SKYE $1.46
- Average True Range (ATR)
- CIGL 0.00
- SKYE 0.10
- MACD
- CIGL 0.00
- SKYE 0.04
- Stochastic Oscillator
- CIGL 0.00
- SKYE 36.90
About CIGL Concorde International Group Ltd Class A Ordinary Shares
Concorde International Group Ltd is an integrated security services provider that combines physical manpower and technology to deliver effective security solutions. The company offers a range of services to enhance security and safety: (1) i-Guarding Services; (2) Man-Guarding Services; and (3) Consultancy and Training Services. Its i-Guarding Services leverages technology to increase efficiency, with a mobile platform and cluster aggregation model of a higher skillset workforce. It has two operating segments, which are (i) security services; and (ii) training school. Key revenue is generated from Security Services.
About SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.